Kingold Pharmaceuticals Authorizes Share Buyback Up to 350 Million Yuan

According to its official announcement on June 29, Kingold Pharmaceuticals (HKEX: 02595) has authorized a share buyback program for its H-shares with a maximum amount of 350 million yuan. The board of directors believes the current trading price undervalues the company's intrinsic value and development prospects. The buyback program aims to enhance shareholder value and demonstrates the board's confidence in the company's long-term growth. Repurchases will be conducted opportunistically in the open market and only when market conditions and the company's financial position are deemed appropriate.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments